Acrivon Therapeutics, Inc. (ACRV) company profile
Close on Nov 17, 2026Market cap $61.28MP/E –Yield –
About Acrivon Therapeutics
Pharmaceutical Preparations, SIC 2834
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision oncology medicines. The company utilizes its proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics (AP3) platform to quantify drug-regulated pathway activity levels inside intact tumor cells in an unbiased manner. Its core pipeline includes ACR-368 (prexasertib), a targeted CHK1 and CHK2 inhibitor undergoing Phase 2b clinical trials for indications such as endometrial cancer, and ACR-2316, a selective dual WEE1/PKMYT1 inhibitor in Phase 1 evaluation. In addition, Acrivon advances ACR-6840 targeting CDK11. The company uses drug-tailored OncoSignature companion diagnostic tests to match targeted therapies with specific patients likely to respond.
The company operates a certified Clinical Laboratory Improvement Amendments (CLIA) laboratory to process patient samples and perform diagnostic testing in-house. Acrivon is headquartered in Watertown, Massachusetts, where it maintains principal executive offices. The company also conducts operations and leases facility space in Sweden.
Summary of the business section of Acrivon Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Acrivon Therapeutics, Inc.
- Founded
- 2018
- Headquarters
- Watertown, MA
- Address
- 480 Arsenal Way, Suite 100 02472
- Phone
- (617) 207-8979
- Website
- acrivon.com
- Employees
- 74, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ACRV
- Exchange
- Nasdaq
- IPO date
- Nov 16, 2022
- Shares outstanding
- 43M, Aug 7, 2026
- Public float
- $20.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1781174
- CUSIP
- 004890109
- ISIN
- US0048901096
- FIGI
- BBG011RWR2Q4
- Share class FIGI
- BBG011RWR2R3
- EIN
- 82-5125532
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kristina Masson | EVP - Business Operations, Director | 2,629,947 |
| Peter Blume-Jensen | President and CEO, Director | 2,615,911 |
| Mary Miller | Chief Legal Officer | 81,202 |
| Michaela Levin | Chief Business Officer | 30,000 |
| Eric Devroe | Chief Operating Officer | 146,349 |
| Katharine Peterson | Chief Accounting Officer | 18,033 |
| Erick Gamelin | Chief Development Officer | 52,592 |
| Adam D. Levy | Chief Financial Officer | 66,008 |
| Mansoor Raza Mirza | Chief Medical Officer | 38,817 |
| Jean-Marie Cuillerot | Chief Medical Officer | – |
| Rasmus Holm-Jorgensen | Chief Financial Officer | 26,088 |
| Santhosh Palani | Director | 9,366 |
| Rajeev M. Shah | Director | – |
| Peter Kolchinsky | Director | – |
| Ra Capital Management, L.P. | Director | – |
| RA Capital Nexus Fund II, L.P. | Director | 9,366 |
| Charles M. Baum | Director | 9,366 |
| Derek DiRocco | Director | 9,366 |
| Capital Healthcare Fund LP RA | Director | 7,914,206 |
| Sharon Shacham | Director | 9,366 |
| Michael John Tomsicek | Director | 9,366 |
| Ivana Magovcevic-Liebisch | Director | 9,366 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Peter Blume-Jensen Chief Executive Officer, President and Director | $709.89K | $1.59M | $410.40K | $6.00K | $2.72M | +36% |
| Kristina Masson Executive Vice President, Business Operations, Director | $594.47K | $573.21K | $251.25K | $6.00K | $1.42M | +19% |
| Eric Devroe Chief Operating Officer | $528.75K | $573.21K | $250.05K | $6.00K | $1.36M | +18% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 16, 2022
- Offer price
- $12.50
- Securities offered
- 7,550,000
- Gross proceeds
- $94.38M
- Exchange
- Nasdaq
- First trading day
- Nov 15, 2022
- First-day close
- $16.64+33.1%
- Lock-up ends (est.)
- May 14, 2023
“Per Share Total Initial public offering price $12.50 $94,375,000 Underwriting discounts and commissions (1) $0.875 $6,606,250 Proceeds, before expenses, to us $11.625 $87,768,750 (1) We refer you to “Underwriting” for additional information regarding total underwriter compensation.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 74 full-time employees and two part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 16, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 7, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?